steatocystoma

Sporadic forms of steatocystoma multiplex have not been shown to be associated with K17 mutations.

A variety of surgical treatment options have been used in the treatment of steatocystoma multiplex.

In steatocystoma multiplex associated with eruptive vellus hair cyst, no K17 mutation has been found.

Steatocystoma may refer to:

Although steatocystoma multiplex has historically been described as an autosomal dominant inherited disorder, most presenting cases are sporadic.

Some authors propose that steatocystoma multiplex is simply a variant of pachyonychia congenita type 2 because they both share the same underlying etiology.

Given these similarities, some postulate that steatocystoma multiplex and eruptive vellus hair cysts are, in fact, variants of the same disease.

The cysts appear similar clinically to steatocystoma multiplex, as well as acneiform eruptions and milia.

"True" sebaceous cysts are relatively rare and are known as steatocystomas or, if multiple, as steatocystoma multiplex.

Steatocystoma multiplex is often associated with eruptive vellus hair cysts (EVHCs).

Steatocystoma simplex is the sporadic solitary tumor counterpart to steatocystoma multiplex.

Steatocystoma multiplex occurs as either a sporadic or autosomal dominant inherited condition characterized by benign sebaceous gland tumors.

The relationship of steatocystoma multiplex to the development of sebaceous glands and common presentation at puberty suggest a hormonal trigger for lesion growth.

Reports of hybrid lesions showing histological features of both steatocystoma multiplex and eruptive vellus hair cysts exist.

Mutations in the gene encoding this protein lead to Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex.

Steatocystoma suppurativa: Treatment is indicated for this scarring inflammatory version of the disorder and involves antimicrobial therapy in combination with incision and drainage.

However, major differences in keratin expression patterns between steatocystoma multiplex and eruptive vellus hair cysts have been elucidated, leading others to believe that they are 2 distinct disease entities.

In previous reports, specific mutations were attributed to early-onset cyst formation in pachyonychia congenita type 2 and steatocystoma multiplex; however, more recent reports suggest that the age of onset is multifactorial.

In the familial form of steatocystoma multiplex, mutations are localized to the keratin 17 (K17) gene in areas identical to mutations found in patients with pachyonychia congenita type 2 (PC-2).

To date, 14 mutations have been described in patients with either steatocystoma multiplex or pachyonychia congenita type 2, all of which are localized to the helix initiation domain (1A domain) of the K17 gene.

First described by Jamieson in 1873, and coined by Pringle in 1899, steatocystoma multiplex (SM) is an uncommon disorder of the pilosebaceous unit characterized by the development of numerous sebum-containing dermal cysts.

Keratin 17 is expressed in several epithelial structures, most notably in sebaceous glands, the outer root sheath of hair follicles, and the nail bed; its expression correlates well to the clinical phenotypic expression of both steatocystoma multiplex and pachyonychia congenita type 2.

Steatocystoma simplex (also known as a "Simple sebaceous duct cyst," and "Solitary steatocystoma") is a cutaneous condition characterized by a skin lesion that occurs with equal frequency in adult women and men, occurring on the face, trunk, or extremities.